Unclassified clinical presentations of chronic inflammatory demyelinating polyradiculoneuropathy

Background To assess the ability of the 2021 European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) clinical criteria for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) to include within their classification the whole spectrum of clinical heterogeneity of the disease and to define the clinical characteristics of the unclassifiable clinical forms. Methods The 2021 EAN/PNS clinical criteria for CIDP were applied to 329 patients fulfilling the electrodiagnostic (and in some cases also the supportive) criteria for the diagnosis of CIDP. Clinical characteristics were reviewed for each patient not strictly fulfilling the clinical criteria (‘unclassifiable’). Results At study inclusion, 124 (37.5%) patients had an unclassifiable clinical presentation, including 110 (89%) with a typical CIDP-like clinical phenotype in whom some segments of the four limbs were unaffected by weakness (‘incomplete typical CIDP’), 10 (8%) with a mild distal, symmetric, sensory or sensorimotor polyneuropathy confined to the lower limbs with cranial nerve involvement (‘cranial nerve predominant CIDP’) and 4 (1%) with a symmetric sensorimotor polyneuropathy limited to the proximal and distal areas of the lower limbs (‘paraparetic CIDP’). Eighty-one (65%) patients maintained an unclassifiable presentation during the entire disease follow-up while 13 patients progressed to typical CIDP. Patients with the unclassifiable clinical forms compared with patients with typical CIDP had a milder form of CIDP, while there was no difference in the distribution patterns of demyelination. Conclusions A proportion of patients with CIDP do not strictly fulfil the 2021 EAN/PNS clinical criteria for diagnosis. These unclassifiable clinical phenotypes may pose diagnostic challenges and thus deserve more attention in clinical practice and research.

[1]  Y. Rajabally,et al.  Application of the 2021 EAN/PNS criteria for chronic inflammatory demyelinating polyneuropathy , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[2]  G. Marfia,et al.  Comparison of the diagnostic accuracy of the 2021 EAN/PNS and 2010 EFNS/PNS diagnostic criteria for chronic inflammatory demyelinating polyradiculoneuropathy , 2022, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  R. Lewis,et al.  European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision , 2021, European journal of neurology.

[4]  M. Dentoni,et al.  Atypical chronic inflammatory demyelinating polyradiculoneuropathy: recent advances on classification, diagnosis, and pathogenesis , 2021, Current opinion in neurology.

[5]  R. Lewis,et al.  European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision , 2021, Journal of the peripheral nervous system : JPNS.

[6]  G. Marfia,et al.  Chronic inflammatory demyelinating polyradiculoneuropathy: can a diagnosis be made in patients not fulfilling electrodiagnostic criteria? , 2020, European journal of neurology.

[7]  S. Kuwabara,et al.  Cranial nerve involvement in typical and atypical chronic inflammatory demyelinating polyneuropathies , 2020, European journal of neurology.

[8]  Jeffrey A. Allen The Misdiagnosis of CIDP: A Review , 2020, Neurology and Therapy.

[9]  B. Jacobs,et al.  Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy , 2019, Journal of the peripheral nervous system : JPNS.

[10]  G. Sobue,et al.  Clinicopathological characteristics of subtypes of chronic inflammatory demyelinating polyradiculoneuropathy , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[11]  D. Moher,et al.  Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L: a systematic review , 2019, Journal of Neurology.

[12]  G. Marfia,et al.  Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[13]  D. Gelinas,et al.  Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy , 2018, Brain and behavior.

[14]  R. Lewis,et al.  CIDP diagnostic pitfalls and perception of treatment benefit , 2015, Neurology.

[15]  M. Mori,et al.  Different electrophysiological profiles and treatment response in ‘typical’ and ‘atypical’ chronic inflammatory demyelinating polyneuropathy , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  T. Maisonobe,et al.  A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy , 2010, Journal of the peripheral nervous system : JPNS.

[17]  J. Pollard,et al.  European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision , 2010, European journal of neurology.

[18]  N. Gilhus,et al.  EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases , 2008, European journal of neurology.

[19]  M. Donaghy,et al.  Chronic dysimmune neuropathy , 2003, Journal of Neurology.

[20]  M. Donaghy,et al.  Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. , 2003, Journal of neurology.